Home >companies >Mylan to buy Abbott’s non-US specialty, branded generics assets

Generic drug maker Mylan Inc. said it would buy Abbott Laboratories’ specialty and branded generics business outside the US in an all-stock transaction valued at about $5.3 billion.

Abbott will receive 105 million shares of the combined company worth.

Subscribe to newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Click here to read the Mint ePaperLivemint.com is now on Telegram. Join Livemint channel in your Telegram and stay updated

Close
×
My Reads Logout